1ProLynx LOGO.png
ProLynx issued US patent for cleavable linker technology on hydrogels
May 30, 2017 20:03 ET | ProLynx LLC
SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable...
1ProLynx LOGO.png
ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders
June 29, 2015 17:21 ET | ProLynx LLC
SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...
1ProLynx LOGO.png
ProLynx Announces Active IND of a Novel Ultra-Long Acting PEG–SN-38 Conjugate to Treat Solid Tumors
June 02, 2015 14:05 ET | ProLynx LLC
SAN FRANCISCO, June 02, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC announced today that an Investigational New Drug (IND) application for their novel, ultra-long acting PEG~SN-38 (PLX-0264; DFP-13318)...
1ProLynx LOGO.png
ProLynx Issued Key Patent for Using Releasable Linkers on Insoluble Carriers
February 04, 2015 10:04 ET | ProLynx LLC
SAN FRANCISCO, Feb. 4, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of a novel platform for half-life extension of injectable drugs – peptides, proteins...
1ProLynx LOGO.png
ProLynx Awarded NSF Phase II Grant for Controlled Drug Release From and Degradation of Hydrogels
November 13, 2014 10:00 ET | ProLynx LLC
SAN FRANCISCO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
1ProLynx LOGO.png
ProLynx Issues U.S. Patent Covering Controlled Release Drug Conjugates
June 17, 2014 16:00 ET | ProLynx LLC
SAN FRANCISCO, June 17, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today...
1ProLynx LOGO.png
RxGen and ProLynx Present Data on Ocular Delivery Platform
May 13, 2014 10:00 ET | ProLynx LLC
SAN FRANCISCO, May 13, 2014 (GLOBE NEWSWIRE) -- RxGen and ProLynx LLC, presented primate study data showing that polyethylene glycols (PEGs) are appropriate supports to extend ocular pharmacokinetics...
1ProLynx LOGO.png
ProLynx Issues U.S. Patent Covering Controlled Drug Release From Dendrimers
April 22, 2014 16:00 ET | ProLynx LLC
SAN FRANCISCO, April 22, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs today...
1ProLynx LOGO.png
ProLynx Publishes Results of Ultralong Half-Life PEG-SN38 Pro-Drug With Lower Intestinal Toxicity
March 27, 2014 16:00 ET | ProLynx LLC
SAN FRANCISCO, March 27, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC today announced a publication in the Journal of Medicinal Chemistry on macromolecular pro-drugs that provide the irinotecan...
1ProLynx LOGO.png
ProLynx Issues U.S. Patent Covering Beta-Eliminative Linkers
March 25, 2014 15:24 ET | ProLynx LLC
SAN FRANCISCO, March 25, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs –...